The preferred anticoagulant for treating venous thromboembolism (VTE) in most patients is Low Molecular Weight Heparin (LMWH). LMWH is favored for its predictable effects and reduced bleeding risks. In certain cases, Direct Oral Anticoagulants (DOACs) may also be appropriate alternatives. ;
The recommended anticoagulant for treating venous thromboembolism (VTE) in most patients is Low Molecular Weight Heparin (LMWH), due to its predictable effects and lower risk of bleeding. Direct Oral Anticoagulants (DOACs) are also appropriate in certain cases. Other options include Unfractionated Heparin (UFH) for immediate needs and Warfarin for long-term management.
;